Early research (Phase 1)Study completedNCT00024934What this trial is testingB-Lymphocyte Stimulator (BLyS) To Treat Selective IgA DeficiencyWho this might be right forIgA Deficiency National Cancer Institute (NCI) 20
Not applicableLooking for participantsNCT07822100What this trial is testingTo Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic StrategiesWho this might be right forIgA Nephropathy (IgAN)Henoch Schönlein Purpura Nephritis Hong Zhang 374
Not applicableLooking for participantsNCT06065852What this trial is testingNational Registry of Rare Kidney DiseasesWho this might be right forAdenine Phosphoribosyltransferase DeficiencyAH AmyloidosisAHL Amyloidosis+81 more UK Kidney Association 35,000
Not applicableUnknownNCT06125457What this trial is testingEpidemiology of IgA Selective Deficiency - Clinical Manifestations and Risk of TransmissionWho this might be right forCOVID-19 University Hospital, Strasbourg, France 120
Testing effectiveness (Phase 2)Looking for participantsNCT06419205What this trial is testingEvaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GWho this might be right forIgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) Glomerulopathy Akebia Therapeutics 30
Not applicableUnknownNCT02712697What this trial is testingIntegrative Medicine of IgA NephropathyWho this might be right forPrimary IgA Nephropathy Shanghai University of Traditional Chinese Medicine 140